CASE REPORT

A 56-year-old man presented with a newly-developed large mass in his left posterior thigh. He had been treated 6 months earlier with palliative chemoradiation for unclassified sarcomas of the cervical spine, the right femoral head, and both lungs. Magnetic resonance imaging revealed a poorly marginated, 8.5-cm, heterogeneously enhancing mass in the left thigh with nodular, heterogeneous bone marrow signal intensity in the right femur neck, in the proximal femoral shaft, and in the pelvic bone, suggesting intramedullary bone metastasis. Wide excision of the thigh mass was performed under the assumption of high-grade sarcoma. The resected mass showed a multinodular, dark yellow, fish-flesh appearance with necrotic foci measuring 10.6×6.4×2.3 cm (Fig. 1).

Microscopically, the tumor showed heterogeneous cellularity with partly cystic changes and a hemangiopericytic vascular pattern. A hypercellular area showed spindle cells or epithelioid cells with high mitotic activity (63/10 HPFs), whereas a hypocellular area and cystic wall showed pleomorphic rhabdoid cells (Fig. 2). The hypercellular area was immunopositive for CD34 (1:500, Immunotech, Marseille, France) and CD99 (1:200, Dako, Glostrup, Denmark), whereas the hypocellular area and cystic wall showed immunoreactivity for desmin (1:200, Dako) and myogenin (1:200, Dako, Carpinteria, CA, USA) (Fig. 3). The patient received adjuvant chemoradiation therapy (pazopanib 2 cycles and 3,000 cGy radiation 7 cycles) and had shown no recurrence after 7 months of follow-up.

DISCUSSION

SFT is a mesenchymal tumor that is characteristically ‘‘patternless’’ with an arborescent vascular frame [5]. It can occur at any site of body and can vary in appearance, including hyaline, cellular, and epithelioid elements. It presents as well-demarcate and slow growing [7]. A malignant form of SFT is rare, and it has been proposed to arise either de novo or within a preexisting benign SFT [8]. There are some reported cases of MSFT arising from benign SFT. Yokoi et al. [8] previously described three cases of malignant transformation from benign SFT. The tumors had both a malignant-looking and a benign-looking component. The malignant-looking component had highly atypical cells with hyperchromatic nuclei and increased mitotic activity and had markedly high expression of p53, Ki-67, and CD34 and immunonegativity for desmin and myogenin, whereas the benign-looking component included low- or intermediate-grade tumors with typical SFT features. Another five cases of de novo MSFT have also been described [8]. These cases had heterogeneous, high- to low-grade pathologic features.

As previously mentioned, only one case of MSFT with heterologous components has been described to date [6]. This patient was a 59-year-old male with a 10-cm-sized mass in the medial aspect of the thigh who underwent a wide excision. The tumor had three distinct characteristics. First, it was a typical SFT with strong immunopositivity for CD34 and Bcl-2 and low mitotic activity (2/10 HPFs). Second, it consisted of pleomorphic cells with nuclear atypia and many bizarre multinucleate tumor giant cells with immunonegativity for CD34 and a high mitotic activity (23/10 HPFs). In addition, this area was also admixed with desmin- and myogenin-immunopositive rhabdomyosarcomatous elements. Third, the tumor showed osteosarcomatous differentiation with distinct malignant osteoid cells. After wide excision, that patient proceeded to postoperative radiotherapy and remained free of disease for 7 months.

In our case, the patient was a 56-year-old man that had a 10.6-cm-sized, newly developed large mass in his left posterior thigh. He had been treated with palliative chemoradiation 6 months earlier for unclassified sarcomas of multiple metastasis. Microscopically, the tumor showed three different components: hypercellular, hypocellular, and partly cystic components. Cystic components presented with a hemangiopericytic vascular pattern. A hypercellular area showed spindle cells or epithelioid cells with high mitotic activity and showed immunopositivity for CD34 and CD99, whereas a hypocellular area and cystic wall showed pleomorphic rhabdoid cells and immunoreactivity for desmin and myogenin. The patient received adjuvant chemoradiation therapy and has shown no recurrence after 7 months of follow-up.

The differential diagnosis of MSFT includes benign and malignant lesions, such as malignant peripheral nerve sheath tumor (MPNST), synovial sarcoma (SS), fibrosarcoma, undifferentiated pleomorphic sarcoma (previously malignant fibrous histiocytoma), and dermatofibrosarcoma protuberans (DFSP) [5,9]. MPNST has features of heterogeneous spindle cells with variable growth pattern and arrangement and has bizarre giant cells, high mitotic activities, and distinguishing patterns of necrosis [10]. MPNST also shows focal immunopositivity for S100 protein.

SS has three major histological subtypes: biphasic, monophasic, and poorly differentiated. The biphasic subtype shows co-existence of epithelioid cells and spindle cells. However, the monophasic subtype is entirely composed of spindle cells; in this case, immunonegativity for CD34 is helpful to exclude the diagnosis [11].

Fibrosarcoma consists of highly cellular fibroblasts with variable collagen production. It has a herringbone-like growth pattern and consists of scant cytoplasm, hyperchromatic nuclei, and variable nucleoli [5]. It also presents immunonegativity for CD34.

Undifferentiated pleomorphic sarcoma has high cellularity lesions, mixed with spindle cells and often rounded histiocyte-like cells. Some cases have extensive fibrous stroma. This tumor has a storiform growth pattern and pleomorphic tumor cells with foamy cytoplasm and marked nuclear atypia. Multinucleated giant cells may also be seen.

DFSP presents with a non-circumscribed, highly cellular lesion and has a storiform growth pattern. Cells are monomorphic and spindly with scant eosinophilic cytoplasm. It usually has no significant pleomorphism and rare histiocytes [5]. DFSP is less deeply located than SFT and usually involves the dermis [12].

Barthelmess et al. [13] identified recurrent somatic fusions of two genes, NGFI-A binding protein 2 (NAB2) and STAT6, located at 12q13, as presumable tumor-initiating events in SFT. Although the authors raised the possibility that specific NAB2-STAT6 fusion variants may be associated with higher risk of aggressive behavior [13], there are no distinct molecular features that differentiate benign from malignant tumors.

Surgical excision has been the standard treatment option for both benign and MSFTs, but late recurrences have been observed [14]. Radiotherapy is often used to improve local control, and chemotherapy is used for lesion that cannot be completely excised [15]. However, the benefits of these adjuvant chemoradiation therapies remain unproven. In conclusion, we present a rare case of MSFT with rhabdomyosarcomatous differentiation. This case report expands our knowledge of the histologic features of MSFT.

Fig. 1.

Magnetic resonance image revealing a well-defined enhancing mass in the postero-medial compartment of the left thigh (arrow) (A), with metastasis in the C2 vertebral body (arrow) (B). (C) Chest computed tomography showing multiple nodules in both lungs. (D) Grossly, a large lobulated mass is observed in the left thigh. The cut surface of the mass is yellow-tan and firm with necrotic foci.

Fig. 2.

Microscopic findings. (A) The mass consists of a hypercellular area (H), a hypocellular area (L), and a cystic area (C). (B) The hypercellular area is composed of short spindle or epithelioid cells with a hemangiopericytic vasculature. (C) The hypocellular area shows plump epithelioid cells with inflammatory cells. (D) The cystic area is unilocular and contacted both the hypercellular and the hypocellular areas.

Fig. 3.

Morphologic and immunohistochemical findings. (A) The hypercellular area is composed of short spindle or epithelioid cells with prominent nucleoli and high mitotic activity (63/10 highpower fields) and shows immunoreactivity for CD34 (B) and immunonegativity for desmin (C) and myogenin (D). (E) The hypocellular area is composed of plump epithelioid cells and shows immunoreactivity for CD34 (F) and strong immunopositivity for desmin (G) and myogenin (H). (I) The cystic component is composed of pleomorphic rhabdoid cells and shows focal immunoreactivity for CD34 (J) and strong immunopositivity for desmin (K) and myogenin (L).

REFERENCES

• 1. Collini P, Negri T, Barisella M, et al. High-grade sarcomatous overgrowth in solitary fibrous tumors: a clinicopathologic study of 10 cases. Am J Surg Pathol 2012; 36: 1202-15. ArticlePubMed
• 2. Rajeev R, Patel M, Jayakrishnan TT, et al. Retroperitoneal solitary fibrous tumor: surgery as first line therapy. Clin Sarcoma Res 2015; 5: 19.ArticlePubMedPMC
• 3. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 2012; 25: 1298-306. ArticlePubMed
• 4. Robinson LA. Solitary fibrous tumor of the pleura. Cancer Control 2006; 13: 264-9. ArticlePubMedPDF
• 5. Fletcher CD, Unni KK, Mertens F. World Health Organization classification of tumours of pathology and genetics tumours of soft tissue and bone. Lyon: IARC Press, 2002.Article
• 6. Thway K, Hayes A, Ieremia E, Fisher C. Heterologous osteosarcomatous and rhabdomyosarcomatous elements in dedifferentiated solitary fibrous tumor: further support for the concept of dedifferentiation in solitary fibrous tumor. Ann Diagn Pathol 2013; 17: 457-63. ArticlePubMed
• 7. Wetzel W, Alexander R. Myxoid liposarcoma: an ultrastructural study of two cases. Am J Clin Pathol 1979; 72: 521-8. ArticlePubMed
• 8. Yokoi T, Tsuzuki T, Yatabe Y, et al. Solitary fibrous tumour: significance of p53 and CD34 immunoreactivity in its malignant transformation. Histopathology 1998; 32: 423-32. ArticlePubMed
• 9. Bishop JA, Rekhtman N, Chun J, Wakely PE Jr, Ali SZ. Malignant solitary fibrous tumor: cytopathologic findings and differential diagnosis. Cancer Cytopathol 2010; 118: 83-9. ArticlePubMed
• 10. Miguchi M, Takakura Y, Egi H, et al. Malignant peripheral nerve sheath tumor arising from the greater omentum: case report. World J Surg Oncol 2011; 9: 33.ArticlePubMedPMC
• 11. Zhang HY, Feng Y, Zhang Z, Gao G, Zhao JS. Synovial sarcoma of the buttocks presenting with a non-healing wound and rapid progression after local resection: a case report. World J Surg Oncol 2012; 10: 125.ArticlePubMedPMC
• 12. Chang D, de Oliveira CR, Saito CF. Malignant solitary fibrous tumour of the extremities. Acta Ortop Bras 2010; 18: 107-9. Article
• 13. Barthelmeß S, Geddert H, Boltze C, et al. Solitary fibrous tumors/hemangiopericytomas with different variants of the NAB2-STAT6 gene fusion are characterized by specific histomorphology and distinct clinicopathological features. Am J Pathol 2014; 184: 1209-18. ArticlePubMed
• 14. Baldi GG, Stacchiotti S, Mauro V, et al. Solitary fibrous tumor of all sites: outcome of late recurrences in 14 patients. Clin Sarcoma Res 2013; 3: 4.ArticlePubMedPMC
• 15. de Perrot M, Kurt AM, Robert JH, Borisch B, Spiliopoulos A. Clinical behavior of solitary fibrous tumors of the pleura. Ann Thorac Surg 1999; 67: 1456-9. ArticlePubMed

Figure & Data

References

Citations

Citations to this article as recorded by  

• A Rare Case of Malignant Solitary Fibrous Tumor on the Scalp
  Kwang-Ryeol Kim, Ki Hong Kim
  Keimyung Medical Journal.2023; 42(2): 107.     CrossRef
• Malignant solitary fibrous tumor of maxilla presenting as proptosis: A case report
  Pravin Kumar, Arpita Jindal, Bhushan Bhalgat, Phanindra Kumar Swain, Raj Govind Sharma
  Journal of Cancer Research and Therapeutics.2023; 19(Suppl 2): S991.     CrossRef
• Recurrent malignant solitary fibrous tumor of the scalp: a case report and literature review
  Ahmed Rabie, Abdulkarim Hasan, Yasein Mohammed, Ayman Abdelmaksoud, Ali A. Rabaan
  Journal of Pathology and Translational Medicine.2022; 56(2): 103.     CrossRef
• Frozen Cytology of Meningeal Malignant Solitary Fibrous Tumor/Hemangiopericytoma
  Myunghee Kang, Na Rae Kim, Dong Hae Chung, Gie-Taek Yie
  Journal of Pathology and Translational Medicine.2019; 53(3): 192.     CrossRef